What will the future hold for clinical research? A recent draft from the FDA provides valuable insight.
In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities." This new guidance will clearly impact the clinical research field, but how?
In this exclusive webinar, Dr. Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.
- Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development?
- Explore the limitations of what we know about prescription drug dosing
- The future of Clinical Research
April 12, 2023 at 11:00 am PDT, 2:00 pm EDT, 7:00 pm GMT
Brought to you by: